Japan Cancer Drug Pipeline Analysis

Publish Date:- Jan-2014       No Of Pages (557)

Electronic Access - Single User License $1500 Buy Now
CD-ROM Mail Delivery $1800Buy Now
Hard Copy Mail Delivery $2100 Buy Now
Electronic Access - Multi-User License $2400 Buy Now


Japan is a significant market for cancer and its related drugs in the Asia-Pacific region. Improved access to healthcare and an increased level of awareness about cancer and the options for its treatment have been major drivers for a rise in the research activities in this country.

With the strong continued support from the government, the Japanese cancer market is expected to grow rapidly in the future years. The government has been the major source of funding for cancer research in all these years. However, of late, many non-governing organizations have also started to support basic and clinical research. This increased trend of forming strategic partnerships would be a major driver of the industry. Additionally, Japan has taken many steps to improve the drug lag system. With the increasing inclusion of Japanese in the global Phase III trials, the drug lag situation is set to improve for many cancers like gastric, non-small cell lung, breast, colorectal, hepatocellular carcinoma, and chronic myelogenous leukemia.

Additionally, licensing agreements are increasingly being used in this market and these have proved to be more efficient from both a strategic and financial point of view in the cancer market in Japan. There would a high upfront values and low development milestones in the form of high probability of approvals in the licensing deals made at a late stage. This is extremely beneficial from a strategic point of view, for the pharma companies in their every-day decision making.

Japan Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of various cancers. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Japan cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “Japan Cancer Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class • ATC Codes



Number of Cancer Drugs in Pipeline by Clinical Phase:

• Research: 23

• Preclinical: 67

• Clinical: 3

• Phase-I: 98

• Phase-I/II: 15

• Phase-II: 26

• Phase-II/III: 3

• Phase-III: 37

• Preregistration: 8

• Registered: 8

• Marketed: 90

• Unknown: 1


Japan is a significant market for cancer and its related drugs in the Asia-Pacific region. Improved access to healthcare and an increased level of awareness about cancer and the options for its treatment have been major drivers for a rise in the research activities in this country.

With the strong continued support from the government, the Japanese cancer market is expected to grow rapidly in the future years. The government has been the major source of funding for cancer research in all these years. However, of late, many non-governing organizations have also started to support basic and clinical research. This increased trend of forming strategic partnerships would be a major driver of the industry. Additionally, Japan has taken many steps to improve the drug lag system. With the increasing inclusion of Japanese in the global Phase III trials, the drug lag situation is set to improve for many cancers like gastric, non-small cell lung, breast, colorectal, hepatocellular carcinoma, and chronic myelogenous leukemia.

Additionally, licensing agreements are increasingly being used in this market and these have proved to be more efficient from both a strategic and financial point of view in the cancer market in Japan. There would a high upfront values and low development milestones in the form of high probability of approvals in the licensing deals made at a late stage. This is extremely beneficial from a strategic point of view, for the pharma companies in their every-day decision making.

Japan Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of various cancers. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Japan cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “Japan Cancer Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class • ATC Codes



Number of Cancer Drugs in Pipeline by Clinical Phase:

• Research: 23

• Preclinical: 67

• Clinical: 3

• Phase-I: 98

• Phase-I/II: 15

• Phase-II: 26

• Phase-II/III: 3

• Phase-III: 37

• Preregistration: 8

• Registered: 8

• Marketed: 90

• Unknown: 1

1. Japan Cancer Drug Market Overview



2. Cancer Drug Clinical Development Phase: Unknown

  2.1 Overview

  2.2 Cancer Drug Profile in Clinical Development Phase



3. Cancer Drug Clinical Development Phase: Research

  3.1 Overview

  3.2 Cancer Drug Profile in Clinical Development Phase



4. Cancer Drug Clinical Development Phase: Preclinical

  4.1 Overview

  4.2 Cancer Drug Profile in Clinical Development Phase



5. Cancer Drug Clinical Development Phase: Clinical

  5.1 Overview

  5.2 Cancer Drug Profile in Clinical Development Phase



6. Cancer Drug Clinical Development Phase: Phase-I

  6.1 Overview

  6.2 Cancer Drug Profile in Clinical Development Phase



7. Cancer Drug Clinical Development Phase: Phase-I/II

  7.1 Overview

  7.2 Cancer Drug Profile in Clinical Development Phase



8. Cancer Drug Clinical Development Phase: Phase-II

  8.1 Overview

  8.2 Cancer Drug Profile in Clinical Development Phase



9. Cancer Drug Clinical Development Phase: Phase-II/III

  9.1 Overview

  9.2 Cancer Drug Profile in Clinical Development Phase



10. Cancer Drug Clinical Development Phase: Phase-III

  10.1 Overview

  10.2 Cancer Drug Profile in Clinical Development Phase



11. Cancer Drug Clinical Development Phase: Preregistration

  11.1 Overview

  11.2 Cancer Drug Profile in Clinical Development Phase



12. Cancer Drug Clinical Development Phase: Registered

  12.1 Overview

  12.2 Cancer Drug Profile in Clinical Development Phase



13. Marketed

  13.1 Overview

  13.2 Marketed Cancer Drug Profile


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name